Apellis CTO granted 45,220 restricted stock units

Apellis Pharmaceuticals reported that Chief Technical Officer Nur Nicholson received a grant of 45,220 shares of common stock on January 28, 2026.

Rhea-AI Filing Summary

Apellis Pharmaceuticals reported that Chief Technical Officer Nur Nicholson received a grant of 45,220 shares of common stock on January 28, 2026. The shares were awarded at a price of $0 per share as part of an equity compensation program.

According to the footnote, this award is in the form of restricted stock units that vest 25% each year over four years from the grant date, subject to continued service. Following this grant, Nicholson beneficially owns 116,338 shares of Apellis common stock in direct ownership.

Insider Trade Summary

Grant/Award: 45,220 shares

Grant/Award 1 txn

Insider Nicholson Nur

Role Chief Technical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	45,220	$0.00	$0.00

Holdings After Transaction: Common Stock — 116,338 shares (Direct)

Footnotes (1)

1. F1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apellis (APLS) report for Nur Nicholson?

Apellis reported an equity grant to CTO Nur Nicholson. On January 28, 2026, Nicholson was awarded 45,220 shares of Apellis common stock at $0 per share as part of a restricted stock unit compensation package.

How many Apellis (APLS) shares does CTO Nur Nicholson now own?

After the reported grant, Nur Nicholson owns 116,338 shares. This total reflects direct beneficial ownership of Apellis common stock following the award of 45,220 restricted stock units on January 28, 2026.

What are the vesting terms of Nur Nicholson’s Apellis (APLS) RSU award?

The restricted stock units vest over four years. The 45,220-unit award granted on January 28, 2026 vests 25% annually on each anniversary of the grant date, conditioned on Nicholson’s continued service with Apellis.

Was the Apellis (APLS) insider award to Nur Nicholson a purchase or a grant?

The transaction was a grant, not an open-market purchase. Form 4 shows transaction code “A” for an acquisition at $0 per share, indicating an equity compensation award of 45,220 restricted stock units to the Chief Technical Officer.

Is Nur Nicholson a major shareholder or officer at Apellis (APLS)?

Nur Nicholson is an officer of Apellis, serving as Chief Technical Officer. The Form 4 indicates officer status and does not classify Nicholson as a 10% owner, while reporting direct beneficial ownership of 116,338 shares after the award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:08 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicholson Nur

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		45,220(1)	A	$0	116,338	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

	/s/ David Watson, attorney-in-fact for Nur Nicholson	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.